PPL Therapeutics plc sidestepped a potential two-year delay in the launch of its fibrin sealant product to seal wounds and stop bleeding by licensing a plasma-derived fibrinogen production system from Bristol-Myers Squibb Co. But PPL (LSE:PTH) still must revamp its transgenic fibrinogen production system, which has encountered both regulatory delays and problems with the fibrinogen itself.

PTH's original product was a three-component fibrin sealant comprised of fibrinogen produced in the milk of transgenic sheep, and thrombin and